司美格鲁肽 作为一种治疗2型糖尿病和长期体重管理的药物， 凭借优秀的 降糖功能和快速的减重效果 这两大标签 ， 它很快就火遍全 球， 被广泛视为"减肥神药 " 。 整理 | GLP1减重宝典内容团队 美国华盛顿大学的胃肠病专家指出，事实上，人体本身就能产生这些药物的 天然版本 ——GLP-1。那究竟 如何促进天然司美格鲁肽生 成，一篇SCI论文给出了答案。 ▍ 天然司美格鲁肽由下肠道产生，可以抑制食欲，减缓胃排空 下肠道中的特殊细菌会吸收你无法消化的食物成分，如纤维和多酚（许多加工食品中去除的植物成分），并将其转化为降低食欲和新陈 代谢的激素分子。这些细菌包括 GLP-1， 这是 Wegovy 和 Ozempic 的天然版本。 GLP-1 和其他激素（如 PYY） 有助于通过胰腺调节血糖。它们还会调节下丘脑神经元告诉您的大脑您已经吃饱了，并让您的胃和肠道 放慢食物沿消化道的移动速度，以便消化。这个系统甚至有一个名字： 结肠制动器。 既然人体能生成天然司美格鲁肽 ， 为什么我们还需要司美格鲁肽等GLP-1类药物？ 这和GLP-1类药物本身的结构不容易降解有关， 且天然司美格鲁肽 是一种由30个氨基酸组成的多肽， ...

Core Insights - Eli Lilly's share prices experienced significant growth in 2023 and 2024 due to excitement over GLP-1 diabetes and weight loss therapies, but have since stabilized between $700 and $900 since mid-2024 [2][9] - Valuation concerns, with a forward P/E ratio of around 27, have contributed to the stock's performance, especially when compared to Novo Nordisk's P/E of 14 [3] - Despite current valuation concerns, there is potential for the stock to catch up over the next five years [4] Revenue and Growth Drivers - Lilly's GLP-1 medication, tirzepatide, has been a key revenue driver, generating $5.3 billion in 2023 and projected to reach $16.5 billion in 2024 [6] - Sales for tirzepatide in the first half of 2025 totaled $14.7 billion, with forecasts predicting annual sales to exceed $62 billion in five years [7] - The company is also developing orforglipron, a promising obesity treatment, expected to generate $12.7 billion in annual sales by 2030 [8] Future Outlook - The stock price has remained stable, but sales from diabetes and obesity treatments are anticipated to grow rapidly [9] - While the premium valuation may decrease, further earnings growth could lead to substantial returns over the next five years [9]

The main difference is that they have different side effects and dosages—and because Wegovy is administered at higher doses, a maximum of 2.4 mg a week, it leads to both greater weight loss and more gastrointestinal side effects. Ozempic is typically administered at 2 mg per week. Each are injected once a week. Some good news on the weight-loss front: Customers can now go to Costco to get Ozempic and Wegovy, brand- name injectable prescription drugs manufactured by drug maker Novo Nordisk, which contain the ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 最近几年，以 司美格鲁肽 为代表的 GLP-1 类药物几乎无处不在，它们帮助了许多人安全的控制糖尿病和减肥，此外，这类药物还能降低心血管疾病风险、治疗 睡眠呼吸暂停、骨关节炎，甚至还有助于戒烟戒酒、缓解阿尔茨海默病等疾病。 GLP-1 类药物的畅销，并非一朝一夕。从发现 GLP-1 激素，解析其作用机制，再开发为糖尿病和肥胖的治疗药物，这一旅程漫长而曲折，跨越了 40 多年时 间，涉及学术界和制药行业的数百名研究人员，而诺贝尔奖至多授予 3 人，如果今年的诺贝尔生理学或医学奖奖授予 GLP-1 的发现和相关药物开发，谁值得获 奖？ 对 GLP-1 的结构和功能的早期认识是基于 Joel Habener、 Jens Juul Holst、 Svetlana Mojsov 、 Dan Drucker 几人的研究，而诺和诺德的研究人员 Lotte Bjerre Knudsen 开发了基于 GLP-1 的药物利拉鲁肽和司美格鲁肽。 如果 GLP-1 研究获得诺贝尔奖的认可，那么获奖者大概率是从这 5 人中产生。而在去年，"诺奖风向标"之一的拉斯克奖授予了其中 3 人 —— Jo ...

GLP-1赛道市场空间巨大（千亿美金），MNC加速布局，看好2025中国GLP-1赛道BD拐点。以诺和诺 德、礼来、再生元、安进、默沙东、赛诺菲、艾伯维等为代表的多家MNC加速完善GLP-1相关管线布 局，多家MNC仍有较强管线布局需求。 近日，辉瑞宣布，拟斥资73亿美元收购减肥药物开发商Metsera，这一大手笔收购被普遍视为辉瑞重返 减肥药赛道的重要信号，也引发了国内资本市场的连锁反应。9月23日，A股市场上，减肥药概念股的 股价普遍承压。 当天，博瑞医药也在投资者互动平台回复称，公司海外市场布局正常推进中。旗下重磅减肥药 BGM0504注射液在美国开展的US bridging临床研究已完成，公司将根据FDA的建议完善III期临床方案 并提交。此外，口服BGM0504片剂以及创新药BGM1812注射液两款药物的减重适应证均已在美国递交 IND申请。 MACD金叉信号形成，这些股涨势不错！ 博瑞医药（维权）GLP-1管线布局全面丰富、产品BIC潜力巨大、临床进度靠前。 GLP-1产品研发迭代方向：多靶点、长效化、口服化、瘦体重流失保护等。中国药企布局全面、差异 化、进展靠前，看好GLP-1板块的国际合作潜力 ...

来源：市场资讯 （来源：动脉新医药） 编者按： 全球视野下的跨国药企深度洞察——创新、博弈与中国答卷 在全球医药产业发展的宏大叙事中，跨国药企始终扮演着关键角色——他们既是科学前沿的探索者，也 是大多市场规则的塑造者，更是各国医疗生态的重要参与者。从FDA到EMA再到NMPA ，从成熟市场 到新兴市场，跨国药企的战略抉择不仅关乎企业自身的兴衰，更深刻影响着全球患者的健康福祉。而在 这一版图中，中国市场也正从"可选项"到"必选项"再升级为"决胜场"，其独特的政策环境、临床需求和 创新潜力，为跨国药企提供了前所未有的机遇与挑战。 我们拟打造《跨国药企洞察》栏目，致力于以全球视野观察跨国药企的发展逻辑，既关注MNC巨头的 顶层战略——辉瑞如何平衡新冠红利后的增长焦虑，强生怎样通过拆分重塑竞争力；也聚焦区域市场的 关键战役——中国医保谈判中的定价艺术，ADC领域中日韩创新药企的竞合博弈；更试图揭示行业本 质问题：在细胞与基因治疗、GLP-1等颠覆性技术浪潮下，未来诸多面临"专利断崖"的跨国药企护城河 是正在加固还是被瓦解？ 与此同时，中国篇章亦无疑是这一洞察的核心维度。无论是将中国纳入全球早期研发体系，还是以"中 国 ...

Group 1 - The core viewpoint of the news highlights the significant growth potential in the global GLP-1 drug market, which is currently dominated by Novo Nordisk and Eli Lilly, with other multinational corporations (MNCs) accelerating their involvement [1][2] - The stock price of Paig BioPharma-B (02565) has increased over 5% recently, with a cumulative increase of more than 3.1 times since its listing, indicating strong market interest and performance [1] - Zhejiang Securities emphasizes that the GLP-1 sector has substantial room for growth in terms of potential patient base and market size, making it a critical area for MNCs in the metabolic disease field [1] Group 2 - PB-718, a key product of Paig BioPharma, is a novel long-acting GLP-1/GCG dual receptor agonist targeting MASH treatment, showing promising clinical results [2] - The clinical trial results for PB-718 indicate a significant reduction in liver fat content, with a mean percentage change of -57.14% after 18 weeks of treatment at a dosage of 1.6mg, outperforming Semaglutide in a shorter treatment duration [2]

Core Insights - An experimental GLP-1 pill named orforglipron has shown significant weight loss results in clinical trials without requiring weekly injections [1] Group 1 - The clinical trial results indicate that orforglipron promotes substantial weight loss [1]

Key Takeaways Novo Nordisk's Ozempic cut major cardiovascular event risk by 23% versus Eli Lilly's Trulicity.Ozempic also showed a 25% reduction in a broader composite endpoint in the REACH study.Novo Nordisk secured EU approval to add cardiovascular benefits to the Rybelsus label.The global GLP-1 market has been in the spotlight for the past couple of years as big pharma players realize its multi-billion-dollar potential and the untapped nature. It is currently dominated by Novo Nordisk (NVO) and Eli Lilly ...

Novo Nordisk A/S NVO looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is starting to resemble UnitedHealth Group Inc.'s UNH rebound playbook.Obesity & Heart Health: Novo's Data SurgeNovo's oral semaglutide 25 mg pill (same molecule as Wegovy) delivered 16.6% average weight loss in people with obesity, with one in three study participants losing 20% or more of their body weight. Improvement ...